down arrow

Cyanotech Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2324373016
USD
0.36
0.01 (2.86%)

Dec 04

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.360.36

52 Week

0.210.57
Valuation
Technical
Day's Volume

CASH

217

Shareholding (Dec 2024)

FII

0.00%

Held by 0 FIIs

DII

98.88%

Held by 1 DIIs

Promoter

0.00%

How big is Cyanotech Corp.?

22-Jun-2025

As of Jun 18, Cyanotech Corp. has a market capitalization of 2.57 million and reported net sales of 23.88 million with a net profit of -4.65 million over the latest four quarters. Shareholder's funds are at 11.81 million, and total assets are 25.11 million.

As of Jun 18, Cyanotech Corp. has a market capitalization of 2.57 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 23.88 million, while the sum of net profit for the same period is -4.65 million.<BR><BR>As of Mar 24, the reporting period shows shareholder's funds at 11.81 million and total assets at 25.11 million.

Read More

What does Cyanotech Corp. do?

22-Jun-2025

Cyanotech Corporation produces natural products from microalgae for the nutritional supplements market and operates as a micro-cap company with a market cap of $2.57 million. As of December 2024, it reported net sales of $6 million but no net profit.

Overview:<BR>Cyanotech Corporation is engaged in the production of natural products derived from microalgae for the nutritional supplements market and operates within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 6 Million (Quarterly Results - Dec 2024)<BR>- Most recent Net Profit: 0 Million (Quarterly Results - Dec 2024)<BR>- Market-cap: USD 2.57 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.82<BR>- Return on Equity: -49.02%<BR>- Price to Book: 0.27<BR><BR>Contact Details:<BR>- Address: 73-4460 Queen Kaahumanu Hwy Ste 102, KAILUA KONA HI: 96740-2637<BR>- Tel: ['1 808 3261353', '1 310 3466131']<BR>- Fax: 1 808 3294533<BR>- Website: https://www.cyanotech.com/

Read More

Who are in the management team of Cyanotech Corp.?

22-Jun-2025

As of March 2022, the management team of Cyanotech Corp. includes Mr. Michael Davis as the Independent Chairman and Dr. Gerald Cysewski as the CEO and Executive Vice Chairman, along with Independent Directors Ms. Nancy Katz, Mr. Walter Menzel, Mr. David Mulder, and Mr. David Vied.

As of March 2022, the management team of Cyanotech Corp. includes the following individuals:<BR><BR>- Mr. Michael Davis, who serves as the Independent Chairman of the Board.<BR>- Dr. Gerald Cysewski, who is the Chief Executive Officer and Executive Vice Chairman of the Board.<BR><BR>Additionally, the Board of Directors features several Independent Directors: Ms. Nancy Katz, Mr. Walter Menzel, Mr. David Mulder, and Mr. David Vied.

Read More

Is Cyanotech Corp. overvalued or undervalued?

20-Sep-2025

As of November 9, 2022, Cyanotech Corp. is considered overvalued and has a risky valuation outlook due to poor financial metrics and significant underperformance compared to the S&P 500.

As of 9 November 2022, the valuation grade for Cyanotech Corp. has moved from expensive to risky, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its current financial metrics, particularly with a Price to Book Value of 0.30, an EV to EBITDA of -5.14, and a ROE of -49.02%. <BR><BR>In comparison to its peers, Cyanotech Corp. has a less favorable EV to EBITDA ratio than Upexi, Inc. at -37.9754 and Natural Alternatives International, Inc. at -7.6875, both of which also carry a risky valuation. The company's stock has significantly underperformed against the S&P 500, with a one-year return of -57.57% compared to the index's 17.14%, reinforcing the notion that it is overvalued in the current market context.

Read More

Is Cyanotech Corp. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Cyanotech Corp. is in a bearish trend with weak strength, indicated by bearish MACD and moving averages, along with significant underperformance against the S&P 500, showing a 1-year return of -57.57%.

As of 9 September 2025, the technical trend for Cyanotech Corp. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and bearish signals from both the Dow Theory and Bollinger Bands on the monthly timeframe. Additionally, the stock has significantly underperformed the S&P 500 across multiple periods, with a 1-year return of -57.57% compared to the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.04

stock-summary
Return on Equity

-36.59%

stock-summary
Price to Book

0.26

Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.57%
0%
28.57%
6 Months
-11.63%
0%
-11.63%
1 Year
4.5%
0%
4.5%
2 Years
-57.65%
0%
-57.65%
3 Years
-71.88%
0%
-71.88%
4 Years
-89.53%
0%
-89.53%
5 Years
-87.23%
0%
-87.23%

Cyanotech Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Cyanotech Corp. technically bullish or bearish?

As of 9 September 2025, the technical trend for Cyanotech Corp. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and bearish signals from both the Dow Theory and Bollinger Bands on the monthly timeframe. Additionally, the stock has significantly underperformed the S&P 500 across multiple periods, with a 1-year return of -57.57% compared to the S&P 500's 17.14%....

Read More

Is Cyanotech Corp. overvalued or undervalued?

As of 9 November 2022, the valuation grade for Cyanotech Corp. has moved from expensive to risky, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its current financial metrics, particularly with a Price to Book Value of 0.30, an EV to EBITDA of -5.14, and a ROE of -49.02%. In comparison to its peers, Cyanotech Corp. has a less favorable EV to EBITDA ratio than Upexi, Inc. at -37.9754 and Natural Alternatives International, Inc. at -7.6875, both of which also carry a risky valuation. The company's stock has significantly underperformed against the S&P 500, with a one-year return of -57.57% compared to the index's 17.14%, reinforcing the notion that it is overvalued in the current market context....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-4.99%
EBIT Growth (5y)
-211.82%
EBIT to Interest (avg)
-1.47
Debt to EBITDA (avg)
1.13
Net Debt to Equity (avg)
0.89
Sales to Capital Employed (avg)
1.22
Tax Ratio
0.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.60%
ROCE (avg)
2.41%
ROE (avg)
2.21%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.30
EV to EBIT
-2.68
EV to EBITDA
-5.14
EV to Capital Employed
0.62
EV to Sales
0.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-22.97%
ROE (Latest)
-49.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.12%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -7.94% vs 1.61% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -50.00% vs -200.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.80",
          "val2": "6.30",
          "chgp": "-7.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.90",
          "val2": "-0.60",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-129.40%",
          "val2": "-70.20%",
          "chgp": "-5.92%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 4.76% vs -0.43% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 39.62% vs -55.88% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.20",
          "val2": "23.10",
          "chgp": "4.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "-2.50",
          "chgp": "76.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.20",
          "val2": "-5.30",
          "chgp": "39.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-103.60%",
          "val2": "-199.00%",
          "chgp": "9.54%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
5.80
6.30
-7.94%
Operating Profit (PBDIT) excl Other Income
-0.30
0.00
Interest
0.20
0.20
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.90
-0.60
-50.00%
Operating Profit Margin (Excl OI)
-129.40%
-70.20%
-5.92%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -7.94% vs 1.61% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -50.00% vs -200.00% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
24.20
23.10
4.76%
Operating Profit (PBDIT) excl Other Income
-0.60
-2.50
76.00%
Interest
0.70
0.70
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.20
-5.30
39.62%
Operating Profit Margin (Excl OI)
-103.60%
-199.00%
9.54%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 4.76% vs -0.43% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 39.62% vs -55.88% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Cyanotech Corp. stock-summary
stock-summary
Cyanotech Corp.
Pharmaceuticals & Biotechnology
Cyanotech Corporation is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The Company's products include Hawaiian Spirulina Pacifica and Hawaiian BioAstin. Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids. Hawaiian BioAstin is a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health. The Company cultivates over two microalgal species from which its product lines, natural astaxanthin products and spirulina products, are derived. The Company produces its algae in Hawaii and manufactures the finished products in Hawaii and California.
Company Coordinates stock-summary
Company Details
73-4460 Queen Kaahumanu Hwy Ste 102 , KAILUA KONA HI : 96740-2637
stock-summary
Tel: 1 808 32613531 310 3466131
stock-summary
https://www.cyanotech.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."